/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BIODESIX INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$7.98 0.0396(3.96%) BDSX at 04 Dec 2025 04:26 PM Diagnostics & Research
Lowest Today 7.89
Highest Today 8.28
Today’s Open 8.06
Prev. Close 7.83
52 Week High 32.20
52 Week Low 3.44
Day’s Range: Low 7.89 High 8.28
52-Week Range: Low 3.44 High 32.20
1 day return -
1 Week return -3.96
1 month return +5.54
3 month return +1732.56
6 month return +2574.92
1 year return +494.05
3 year return +458.74
5 year return -48.48
10 year return -

Institutional Holdings

Telemark Asset Management, LLC 0.28

Bryn Mawr Trust Company 0.21

Birchview Capital, LP 0.20

Vanguard Group Inc 0.13

Vanguard Total Stock Mkt Idx Inv 0.08

Perceptive Advisors LLC 0.07

Monashee Investment Management LLC 0.07

SILVERARC CAPITAL MANAGEMENT, LLC 0.04

Perkins Capital Management Inc 0.04

Vanguard Institutional Extnd Mkt Idx Tr 0.03

GSA Capital Partners LLP 0.03

Balyasny Asset Management LLC 0.03

Geode Capital Management, LLC 0.03

BlackRock Inc 0.02

Fidelity Extended Market Index 0.01

State Street Corp 0.01

Shay Capital LLC 0.01

Spears Abacus Advisors LLC 0.01

XTX Topco Ltd 0.01

Stephens Inc 0.01

Northern Trust Corp 0.01

HighTower Advisors, LLC 0.01

Blair William & Co 0.00

Fidelity Total Market Index 0.00

Extended Equity Market Fund K 0.00

Bridgeway Ultra-Small Company Market 0.00

Fidelity Series Total Market Index 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Spartan Total Market Index Pool G 0.00

Fidelity Nasdaq Composite Index 0.00

Spartan Extended Market Index Pool F 0.00

Vanguard Instl Ttl Stck Mkt Idx Tr 0.00

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

Extended Equity Market Fund M 0.00

Market Status

Strong Buy: 4

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 62.64 M

PB Ratio 54.1301

PE Ratio 0.0

Enterprise Value 122.20 M

Total Assets 97.24 M

Volume 59376

Company Financials

Annual Revenue FY23:44026000 44.0M, FY22:38212000 38.2M, FY21:54506000 54.5M, FY20:45557000 45.6M, FY19:24552000 24.6M

Annual Profit FY23:31084000 31.1M, FY22:24058000 24.1M, FY21:23988000 24.0M, FY20:23559000 23.6M, FY19:18478000 18.5M

Annual Net worth FY23:-63345000 -63.3M, FY22:-80388000 -80.4M, FY21:-44480000 -44.5M, FY20:-36473000 -36.5M, FY19:-31355000 -31.4M

Quarterly Revenue Q3/2025:21768000 21.8M, Q2/2025:20018000 20.0M, Q1/2025:17958000 18.0M, Q3/2024:18151000 18.2M, Q2/2024:17925000 17.9M

Quarterly Profit Q3/2025:17662000 17.7M, Q2/2025:15987000 16.0M, Q1/2025:14255000 14.3M, Q3/2024:13972000 14.0M, Q2/2024:14048000 14.0M

Quarterly Net worth Q3/2025:-8716000 -8.7M, Q2/2025:-11468000 -11.5M, Q1/2025:-11101000 -11.1M, Q3/2024:-10258000 -10.3M, Q2/2024:-10808000 -10.8M

Fund house & investment objective

Company Information Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Organisation Diagnostics & Research

Employees 273

Industry Diagnostics & Research

CEO Mr. Scott Hutton

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow